An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma

被引：3
|
作者：
Abou-Alfa, G. K. [1 ]
Yoon, J. H. [2 ]
Modiano, M. [3 ]
Ryoo, B. Y. [4 ]
Yau, T. [5 ]
Freilich, B. [6 ]
Knox, J. [7 ]
Ly, M. [1 ]
Ahmed, H. [8 ]
Gahir, S. [8 ]
Niforos, D. [8 ]
Kowalski, M. [8 ]
Kelley, R. K. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Med, 1275 York Ave, New York, NY 10021 USA
[2] Seoul Natl Univ Hosp, Med, Seoul, South Korea
[3] Arizona Clin Res Ctr, Oncol, Tucson, AZ USA
[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Queen Mary Hosp, Med, Hong Kong, Hong Kong, Peoples R China
[6] Kansas City Res Inst, Oncol, Kansas City, MO USA
[7] Princess Margaret Hosp, Med, Toronto, ON, Canada
[8] Arbutus Biopharma Corp, Dev, Burnaby, BC, Canada
[9] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32646-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
46
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [1] An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma
    El Dika, Imane
    Lim, Ho Yeong
    Yong, Wei Peng
    Lin, Chia-Chi
    Yoon, Jung-Hwan
    Modiano, Manuel
    Freilich, Bradley
    Choi, Hye Jin
    Chao, Tsu-Yi
    Kelley, Robin K.
    Brown, Joanne
    Knox, Jennifer
    Ryoo, Baek-Yeol
    Yau, Thomas
    Abou-Alfa, Ghassan K.
    [J]. ONCOLOGIST, 2019, 24 (06): : 747 - E218
  • [2] Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia
    Huetter, Marie-Luise
    Fiedler, Walter
    Kuendgen, Andrea
    Krauter, Juergen
    von Lilienfeld-Toal, Marie
    Kayser, Sabine
    Rafler, Heidi
    Doehner, Hartmut
    Schlenk, Richard F.
    [J]. BLOOD, 2010, 116 (21) : 1350 - 1351
  • [3] A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors.
    Ramanathan, Ramesh K.
    Hamburg, Solomon I.
    Borad, Mitesh J.
    Seetharam, Mahesh
    Kundranda, Madappa N.
    Lee, Peter
    Fredlund, Paul
    Gilbert, Mark
    Mast, Cathy
    Semple, Sean C.
    Judge, Adam D.
    Crowell, Brynne
    Vocila, Linda
    MacLachlan, Ian
    Northfelt, Donald W.
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [4] A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies
    Lubner, Sam Joseph
    Mullvain, Jacqueline
    Perlman, Scott
    Pishvaian, Michael
    Mortimer, Joanne
    Oliver, Katherine
    Heideman, Jennifer
    Hall, Lance
    Weichert, Jamey
    Liu, Glenn
    [J]. CANCER INVESTIGATION, 2015, 33 (10) : 483 - 489
  • [5] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    [J]. PANCREAS, 2017, 46 (03) : 437 - 437
  • [7] CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY
    Stemmer, S. M.
    Benjaminov, O.
    Medalia, G.
    Ciuraru, N. B.
    Silverman, M. H.
    Bar-Yehuda, S.
    Fishman, S.
    Harpaz, Z.
    Farbstein, M.
    Cohen, S.
    Patoka, R.
    Singer, B.
    Kerns, W. D.
    Fishman, P.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S555 - S555
  • [8] CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
    Stemmer, Salomon M.
    Benjaminov, Ofer
    Medalia, Gal
    Ciuraru, Noab B.
    Silverman, Michael H.
    Bar-Yehuda, Sara
    Fishman, Sari
    Harpaz, Zivit
    Farbstein, Motti
    Cohen, Shira
    Patoka, Renana
    Singer, Barak
    Kerns, William D.
    Fishman, Pnina
    [J]. ONCOLOGIST, 2013, 18 (01): : 25 - 26
  • [9] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Kanai, Fumihiko
    Obi, Shuntaro
    Fujiyama, Shigetoshi
    Shiina, Shuichiro
    Tamai, Hideyuki
    Mochizuki, Hitoshi
    Koike, Yukihiro
    Imamura, Jun
    Yamaguchi, Takayoshi
    Saida, Isamu
    Yokosuka, Osamu
    Omata, Masao
    [J]. HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 94 - 103
  • [10] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Fumihiko Kanai
    Shuntaro Obi
    Shigetoshi Fujiyama
    Shuichiro Shiina
    Hideyuki Tamai
    Hitoshi Mochizuki
    Yukihiro Koike
    Jun Imamura
    Takayoshi Yamaguchi
    Isamu Saida
    Osamu Yokosuka
    Masao Omata
    [J]. Hepatology International, 2014, 8 : 94 - 103
12345